<DOC>
	<DOCNO>NCT02922764</DOCNO>
	<brief_summary>Study RGX-104-001 Phase 1 , first-in-human , dose escalation expansion study RGX-104 , oral small molecule target liver X receptor ( LXR ) . RGX-104 activates LXR , result depletion myeloid-derived suppressor cell ( MDSCs ) well tumor blood vessel . MDSCs block ability T-cells cell immune system attack tumor . During dose escalation stage , multiple dos schedule orally administer RGX-104 evaluated patient advance solid tumor lymphoma ( i.e. , locally advance unresectable , metastatic ) progressive disease ( PD ) available standard systemic therapy standard systemic therapy relevant impact . In expansion stage study , additional patient melanoma , non-small cell lung cancer , epithelial ovarian carcinoma , breast cancer treat MTD ( maximum test dose MTD identify , dose MTD evidence suggest favorable risk/benefit profile ) provide characterization RGX-104 safety , efficacy , PK , pharmacodynamics , include biomarkers immunologic activity LXR target activation .</brief_summary>
	<brief_title>A Study RGX-104 Patients With Advanced Solid Malignancies Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . The patient must histologic cytologic evidence malignant solid tumor lymphoma ( histology ) must disease resistant relapse follow available standard systemic therapy , standard systemic therapy reasonable therapy likely result clinical benefit . 2 . The patient must advance disease , define cancer either metastatic locally advanced unresectable ( additional radiation therapy locoregional therapy consider feasible ) . 3 . The patient must disease measurable standard image technique ( exclude patient prostate cancer PSA &gt; 2 bone disease document bone scan imaging ) , per immunerelated response criterion ( irRC ; tumor type except lymphoma ) International Working Group ( IWG ) revise response criterion malignant lymphoma ( lymphoma ) . For patient prior radiation therapy , measurable lesion must outside prior radiation field ( ) , unless disease progression document disease site subsequent radiation . 4 . The patient ≥18 year old . 5 . The patient ECOG PS ≤1 . 6 . The patient adequate baseline organ function , demonstrate following : Serum creatinine ≤1.5 time institutional upper limit normal ( ULN ) calculate creatinine clearance &gt; 30 mL/min ; Serum albumin ≥2.5 g/dl ; Bilirubin ≤1.5 time institutional ULN ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 time institutional ULN ( patient hepatic metastasis must AST/ALT ≤5 time ULN ) ; For patient take warfarin : international normalized ratio ( INR ) ≤1.5 prothrombin time ( PT ) ≤1.5 time ULN ; either partial thromboplastin time activate partial thromboplastin time ( PTT aPTT ) ≤1.5 time ULN . For patient take warfarin : INR &lt; 3.5 . 7 . The patient adequate baseline hematologic function , demonstrate following : Absolute neutrophil count ( ANC ) ≥1.5x10^9/L Hemoglobin ≥8 g/dL red blood cell ( RBC ) transfusion prior 14 day Platelet count ≥100x10^9/L platelet transfusion prior 14 day 8 . The patient normal leave ventricular ejection fraction ( LVEF ) per institutional criterion determine either echocardiography ( ECHO ) multigated acquisition ( MUGA ) scan . 9 . If patient woman child bear potential ( WOCBP ) , negative serum urine pregnancy test within 2 week prior treatment . 10 . The patient ( male female ) agree use acceptable contraceptive method duration time study , continue use acceptable contraceptive method 1 month last treatment RGX104 . 11 . The patient sign informed consent prior initiation studyspecific procedure treatment . 12 . The patient able adhere study visit schedule protocol requirement , include followup survival assessment . 13 . Tumor tissue ( minimum 5 10 unstained slide , paraffin block ) , ideally patient 's recent biopsy , must deliver patient 's local institution site prior treatment RGX104 . 1 . The patient persistent clinically significant toxicity ( Grade ≥2 ) previous anticancer therapy ( exclude Grade 2 chemotherapyrelated neuropathy alopecia permit , exclude Grade 23 laboratory abnormality associate symptom , consider clinically significant Investigator , manage available medical therapy ) . 2 . The patient receive treatment chemotherapy , externalbeam radiation , systemic anticancer therapy within 14 day prior RGX104 administration ( 42 day prior nitrosourea mitomycinC ; patient advanced prostate cancer receive luteinizing hormone release hormone ( LHRH ) agonists permit onto study continue use agent study treatment ) . 3 . The patient receive treatment investigational systemic anticancer agent within 14 day prior RGX104 administration . 4 . The patient previously receive treatment RGX104 another investigational agent know LXR agonist . 5 . The patient additional active malignancy may confound assessment study endpoint . Patients past cancer history ( active malignancy within 2 year prior study entry ) substantial potential recurrence must discuss Sponsor study entry . Patients follow concomitant neoplastic diagnosis eligible : nonmelanoma skin cancer , carcinoma situ ( include transitional cell carcinoma , cervical intraepithelial neoplasia , melanoma situ ) , organconfined prostate cancer evidence progressive disease . 6 . The patient clinically significant cardiovascular disease ( e.g. , uncontrolled New York Heart Association Class 3 4 congestive heart failure , uncontrolled angina , history myocardial infarction , unstable angina stroke within 6 month prior study entry , uncontrolled hypertension clinically significant arrhythmia control medication ) . 7 . The patient uncontrolled , clinically significant pulmonary disease ( e.g. , chronic obstructive pulmonary disease , pulmonary hypertension ) opinion Investigator would put patient significant risk pulmonary complication study . 8 . The patient know active suspect brain leptomeningeal metastasis ( central nervous system [ CNS ] imaging require prior study entry unless clinical suspicion CNS involvement ) . Patients stable , treated brain metastasis eligible provide evidence CNS disease growth image least 2 month follow radiation therapy locoregional ablative therapy CNS . 9 . The patient condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day prior RGX104 administration . Inhaled topical steroid adrenal replacement dos &gt; 10 mg daily prednisone equivalent permit absence active autoimmune disease . 10 . The patient uncontrolled intercurrent illness include , limited , uncontrolled infection , disseminate intravascular coagulation , psychiatric illness/social situation would limit compliance study requirement . 11 . The patient pregnant breast feeding . 12 . The patient know positive status human immunodeficiency virus active chronic Hepatitis B Hepatitis C. 13 . The patient oxygendependent . 14 . The patient history pancreatitis . 15 . The patient Grade ≥2 hypercholesterolemia ( total cholesterol &gt; 300 mg/dL &gt; 7.75 mmol/L ) and/or hypertriglyceridemia ( triglyceride &gt; 300 mg/dL ≥3.42 mmol/L ) fast state . 16 . QTcF &gt; 450 msec ( male ) &gt; 470 msec ( female ) . 17 . The patient cataract Grade ≥2 posterior subcapsular cataract , cortical cataract , nuclear opalescence , nuclear color base Lens Opacities Classification System III ( LOCS III ) . 18 . The patient require statin ( e.g. , rosuvastatin , atorvastatin , etc . ) therapy . 19 . The patient require treatment medication strong inhibitor CYP3A4 ( boceprevir , clarithromycin , conivaptan , grapefruit juice , indinavir , itraconazole , ketoconazole , lopinavir/ritonavir , mibefradil , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telaprevir , telithromycin , voriconazole ) . 20 . The patient require treatment pH elevate agent , include H2 blocker , proton pump inhibitor , antacid . If medication consider medically necessary , patient discuss Medical Monitor . 21 . The patient medical condition opinion Investigator place patient unacceptably high risk toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Solid malignancy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Epithelial ovarian carcinoma</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>EOC</keyword>
	<keyword>BC</keyword>
	<keyword>LXR</keyword>
	<keyword>ApoE</keyword>
	<keyword>mBC</keyword>
</DOC>